International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 2 , Pages 325-334 , 1 June 2001

The 1989 patterns of care study for prostate cancer: five-year outcomes

  • Paul J Chuba, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA
    • Corresponding Author InformationReprint requests to: Paul J. Chuba, M.D., Ph.D., Dept. of Radiation Oncology, St. John Hospital and Medical Center, 22101 Moross, Detroit, MI 48236. Tel: (313) 343-3750; Fax: (313) 343-5186
    • ,
  • Jennifer Moughan, M.S.

      Affiliations

    • American College of Radiology, Philadelphia, PA, USA
    • ,
  • Jeffrey D Forman, M.D.

      Affiliations

    • Department of Radiation Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA
    • ,
  • Jean Owen, Ph.D.

      Affiliations

    • American College of Radiology, Philadelphia, PA, USA
    • ,
  • Gerald Hanks, M.D.

      Affiliations

    • American College of Radiology, Philadelphia, PA, USA
    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

,Accepted 12 January 2001.

References 

  1. Leibel SA, Hanks GE, Kramer S. Patterns of care outcome studies (Results of the national practice in adenocarcinoma of the prostate). Int J Radiat Oncol Biol Phys. 1984;10:401–409
  2. Hanks GE, Diamond JJ, Krall JM, et al.  A ten year follow-up of 682 patients treated for prostate cancer with radiation therapy in the United States. Int J Radiat Oncol Biol Phys. 1987;13:499–505
  3. Hanks GE. External-beam radiation therapy for clinically localized prostate cancer (Patterns of care studies in the United States). NCI Monog. 1988;7:75–84
  4. Hanks GE, Hanlon A, Owen JB, et al.  Patterns of radiation treatment of elderly patients with prostate cancer. Cancer. 1994;74:2174–2177
  5. Pilepich MV, Bagshaw MA, Asbell SO, et al.  Definitive radiotherapy in resectable (Stage A2 and B) carcinoma of the prostate—results of a nationwide overview. Int J Radiat Oncol Biol Phys. 1987;13:659–663
  6. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localized prostate cancer. Lancet. 1997;349:906–910
  7. Smart CR. The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer. 1997;80:1835–1844
  8. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol. 1994;152:1786–1791
  9. Cox DR. Regression model and life tables. J R Stat Soc. 1972;34:187–220
  10. Hanks GE, Krall JM, Hanlon AL, et al.  Patterns of care and RTOG studies in prostate cancer (Long-term survival, hazard rate observations, and possibilities of cure). Int J Radiat Oncol Biol Phys. 1994;8:39–45
  11. Hanks GE, Hanlon A, Schultheiss T, et al.  Early prostate cancer (The national results of radiation treatment from the patterns of care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation). J Urol. 1994;152:1775–1780
  12. Fowler FL, Barry MJ, Lu-Yao G, et al.  Outcomes of external-beam radiation therapy for prostate cancer (A study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas). J Clin Oncol. 1996;14:2258–2265
  13. Zeitman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to T2 adenocarcinoma of the prostate (New insights into outcome from repeat biopsy and prostate specific antigen follow-up). J Urol. 1994;152:1806–1812
  14. Zelefsky MJ, Leibel SA, Gaudin PB, et al.  Dose- escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  15. Hanks GE, Hanlon AL, Schultheiss TE, et al.  Dose escalation with 3D conformal treatment (Five year outcomes, treatment optimization, and future directions). Int J Radiat Oncol Biol Phys. 1998;41:501–510
  16. Gerber RL, Smith AR, Owen J, et al.  Patterns of care survey results (Treatment planning for carcinoma of the prostate). Int J Radiat Oncol Biol Phys. 1995;33:803–888
  17. Ennis RD, Malyszko BK, Heitjan DF, et al.  Changes in biochemical disease-free survival rates as a result of adoption of the consensus conference definition in patients with clinically localized prostate cancer treated with external-beam radiotherapy. Int J Radiat Oncol Biol Phys. 1998;41:511–517
  18. American Society for Therapeutic Radiation and Oncology Consensus Panel. Consensus statement. Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  19. Zeitman AL, Tibbs MK, Dallow KC, Smith CT, Althausen AF. Relapse following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1992;40:159–162
  20. Zeitman AL, Coen JJ, Shipley WU, et al.  Radical radiation therapy in the management of prostatic adenocarcinoma. The initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 1994;151:640–645
  21. Zagars GK, Geara FB, Pollack A; et al. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer 1994;73:1904–1912. For T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786–1791.
  22. Ziaja EL, Martinez AA, Horwitz EM, Vicini FA. Optimal reporting of treatment outcome after external beam radiation therapy for prostate cancer. Proceedings of the 40th Annual ASTRO Meeting. Int J Radiat Oncol Biol Phys. 1998;42(Suppl.):299
  23. D’Amico AV, Whittington R, Malkowicz B, et al.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  24. Ragde H, Eigamal A, Snow PB, et al.  Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma. Cancer. 1998;83:989–1001
  25. Pisansky TM, Chan SS, Earle JD, et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1993;11:2158–2167
  26. Partin AW, Pund CR, Clemens JQ, et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713
  27. Partin AW, Kattan MW, Subong ENP, et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer (A multi-institutional update). JAMA. 1997;277:1445–1451
  28. Frazier HA, Robertson JE, Humphrey PA, et al.  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy?. J Urol. 1993;149:516
  29. Teshima T, Hanlon AM, Hanks GE. Pretreatment prostate-specific antigen values in patients with prostate cancer (1989 patterns of care study process survey). Int J Radiat Oncol Biol Phys. 1995;33:809–814
  30. Hanks GE, Leibel SA, Krall JM, et al.  Patterns of care studies (Dose-response observations for local control of adenocarcinoma of the prostate). Int J Radiat Oncol Biol Phys. 1985;11:153–157
  31. Pinover WK, Hanlon AL, Horowitz EM, et al.  Defining the appropriate dose for prostate cancer with PSA < 10 ng/ml. Int J Radiat Oncol Biol Phys. 1998;42(Suppl.):142
  32. Lyons JA, Kupelian PA. Importance of radiation dose in the treatment of stage T1-T2 adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys. 1998;42(Suppl.):308
  33. Pollack A, Zagars GK, Smith LG, et al.  Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904–3911
  34. Pilepich MV, Krall JM, Al-Sarraf M, et al.  Androgen deprivation with radiation therapy compared with radiation alone for locally advanced prostate carcinoma (A randomized phase III trial of the Radiation Therapy Oncology Group). Urology. 1995;45:616–623
  35. Pilepich MV, Caplan R, Byhardt RW, et al.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy. Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013–1021
  36. Zincke H, Blute ML, Fallen MJ, et al.  Radical prostatectomy for stage A adenocarcinoma of the prostate (Staging errors and their implications for treatment recommendations and disease outcome). J Urol. 1991;146:1053
  37. Laverdiere J, Gomez JL, Cusan L, et al.  Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:247–252
  38. Zagars GK, Hohnson DE, von Eschenbach AC, et al.  Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate (Long-term results of a prospective randomized study). Int J Radiat Oncol Biol Phys. 1988;14:1085–1091
  39. Bolla M, Gonzalez D, Warde P, et al.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  40. Roach M, Lu J, Pilepich MV, et al.  Long-term survival after radiotherapy alone (Radiation Therapy Oncology Group prostate cancer trials). J Urol. 1999;161:864–868

☆ This work is supported by NCI Grant CA 65435 and Contract NCI-NO1-87275.

PII: S0360-3016(01)01478-X

International Journal of Radiation Oncology * Biology * Physics
Volume 50, Issue 2 , Pages 325-334 , 1 June 2001

Article Tools

* Image Usage & Resolution